← Leaderboards
Nathanael Schiander Gray
Dana-Farber Cancer Inst
$36,761,550
Attributed
$60,606,157
Total exposure
27
Grants
18
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.9M · FY2006–25$10M$7.5M$5M$2.5M$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$60,606,157 · 27
By mechanism
R01$45,218,046 · 15
U01$3,287,745 · 1
U54$2,585,675 · 3
OT2$2,221,836 · 1
RC2$1,984,285 · 1
P01$1,798,505 · 2
Top collaborators
- Pasi A Janne15 shared
- Priscilla Li-Ning Yang14 shared
- Michael J Eck10 shared
- Eric Sebastian Fischer8 shared
- Debopam Chakrabarti6 shared
- Elizabeth A Winzeler6 shared
- Ari M. Melnick5 shared
- Kwok Kin Wong5 shared
Most similar at Dana-Farber Cancer Inst
Same institution · by research overlap
- Alex Kentsis$10,070,317
- Jarrod A. Marto$4,866,870
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistancePharmaceutical ChemistryInhibitor/AntagonistSmall MoleculeMalignant NeoplasmsDesignLeadIn VivoStructurePharmaceutical PreparationsBiochemicalKinase InhibitorBaseMutantTumorProteinsPropertyMutationPharmacologyExhibitsCellsPhosphotransferasesNovel TherapeuticsMouse Model
Grant awards (134)
PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors$1,285,694
OT2 · FY2025 · CA · contact PI
Plasmodium Protein Kinase Focused Antimalarials Discovery$755,961
R01 · FY2025 · AI
Targeting CDK7 in CCNE1-amplified Ovarian Cancer$698,713
R01 · FY2025 · CA · contact PI
Degrading therapeutically important kinases using small molecules$672,038
R01 · FY2025 · CA · contact PI
HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL$614,155
R01 · FY2025 · CA
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$490,549
R01 · FY2025 · CA
Cancer Therapeutics$169,872
P30 · FY2025 · CA · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2024 · AI
PROTECT - Harnessing PROTEin degradation for Advanced Childhood Tumors$936,142
OT2 · FY2024 · CA · contact PI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$835,944
R01 · FY2024 · AI
Plasmodium Protein Kinase Focused Antimalarials Discovery$762,579
R01 · FY2024 · AI
Degrading therapeutically important kinases using small molecules$685,073
R01 · FY2024 · CA · contact PI
Targeting CDK7 in CCNE1-amplified Ovarian Cancer$663,775
R01 · FY2024 · CA · contact PI
HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL$510,464
R01 · FY2024 · CA
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$466,022
R01 · FY2024 · CA
Cancer Therapeutics$55,542
P30 · FY2024 · CA · contact PI
Plasmodium Protein Kinase Focused Antimalarials Discovery$46,379
R01 · FY2024 · AI
Plasmodium Protein Kinase Focused Antimalarials Discovery$9,412
R01 · FY2024 · AI
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2023 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$835,944
R01 · FY2023 · AI
Plasmodium Protein Kinase Focused Antimalarials Discovery$769,003
R01 · FY2023 · AI
Targeting CDK7 in CCNE1-amplified Ovarian Cancer$684,738
R01 · FY2023 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$480,738
R01 · FY2023 · CA
HIJACKING CANCER DRIVERS TO ACTIVATE PROAPOPTOTIC GENES IN DLBCL$439,147
R01 · FY2023 · CA
Degrading therapeutically important kinases using small molecules$389,510
R01 · FY2023 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$257,105
R01 · FY2023 · CA · contact PI
Cancer Therapeutics$55,542
P30 · FY2023 · CA · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$961,202
R01 · FY2022 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$810,874
R01 · FY2022 · AI
Plasmodium Protein Kinase Focused Antimalarials Discovery$801,255
R01 · FY2022 · AI
Targeting CDK7 in CCNE1-amplified Ovarian Cancer$727,068
R01 · FY2022 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$480,738
R01 · FY2022 · CA
Degrading therapeutically important kinases using small molecules$220,171
R01 · FY2022 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$168,336
R01 · FY2022 · CA · contact PI
Cancer Therapeutics$55,542
P30 · FY2022 · CA · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$851,884
R01 · FY2021 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$811,132
R01 · FY2021 · AI
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$656,426
U01 · FY2021 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2021 · CA
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$490,549
R01 · FY2021 · CA
Degrading therapeutically important kinases using small molecules$365,491
R01 · FY2021 · CA · contact PI
Core A: Medicinal Chemistry$290,534
P01 · FY2021 · CA · contact PI
Degrading therapeutically important kinases using small molecules$284,744
R01 · FY2021 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$199,385
R01 · FY2021 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$177,026
P30 · FY2021 · CA · contact PI
Targeting ALK through Degradation and Allosteric Inhibitors$173,887
R01 · FY2021 · CA · contact PI
Validating the Flavivirus Envelope Protein as an Antiviral Target$833,361
R01 · FY2020 · AI
Small molecule-induced degradation of dengue proteins as an antiviral strategy$829,756
R01 · FY2020 · AI
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2020 · CA
Degrading therapeutically important kinases using small molecules$650,235
R01 · FY2020 · CA · contact PI
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$629,612
U01 · FY2020 · CA
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$467,339
R01 · FY2020 · CA
Targeting ALK through Degradation and Allosteric Inhibitors$373,272
R01 · FY2020 · CA · contact PI
Core A: Medicinal Chemistry$290,534
P01 · FY2020 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$176,913
P30 · FY2020 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$2,949
P30 · FY2020 · CA · contact PI
Degrading therapeutically important kinases using small molecules$650,235
R01 · FY2019 · CA · contact PI
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$636,731
U01 · FY2019 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$635,224
R01 · FY2019 · CA
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors$524,708
R01 · FY2019 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$453,318
R01 · FY2019 · CA
Targeting ALK through Degradation and Allosteric Inhibitors$373,272
R01 · FY2019 · CA · contact PI
Core A: Medicinal Chemistry$290,534
P01 · FY2019 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$175,282
P30 · FY2019 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$6,169
P30 · FY2019 · CA · contact PI
Chemistry/Structural Core B$1,753,647
U54 · FY2018 · CA · contact PI
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$661,067
U01 · FY2018 · CA
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$654,869
R01 · FY2018 · CA
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors$540,936
R01 · FY2018 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$425,882
R01 · FY2018 · CA
Core A: Medicinal Chemistry$290,534
P01 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$176,944
P30 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$11,431
P30 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$5,849
P30 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$5,123
P30 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$3,835
P30 · FY2018 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$1,603
P30 · FY2018 · CA · contact PI
Targeting the transcriptional and epigenetic landscape in chemo-refractory Small-Cell Lung Cancer$703,909
U01 · FY2017 · CA
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$699,439
R01 · FY2017 · CA · contact PI
Development of selective Pin1 inhibitors to target a common oncogenic mechanism$673,119
R01 · FY2017 · CA
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors$540,936
R01 · FY2017 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$425,882
R01 · FY2017 · CA
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2017 · CA
Core A: Medicinal Chemistry$290,608
P01 · FY2017 · CA · contact PI
Shared Resource 07: Medicinal Chemistry$157,500
P30 · FY2017 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$700,976
R01 · FY2016 · CA · contact PI
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors$540,936
R01 · FY2016 · CA · contact PI
Development and Application of Selective Covalent Cdk7 Inhibitors$501,164
R01 · FY2016 · CA · contact PI
Discovery and optimization of novel mutant-selective allosteric inhibitors of EGFR T790M$425,882
R01 · FY2016 · CA
Chemical Tools for the Study of Dengue Virus Entry$349,821
R01 · FY2016 · AI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2016 · CA
Chemistry$39,714
P01 · FY2016 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$708,042
R01 · FY2015 · CA · contact PI
Development of covalent PIP4K2 inhibitors for the treatment of p53 deficient lung tumors$540,936
R01 · FY2015 · CA · contact PI
Developing Selective EphA2 Inhibitors for the treatment of Cancer$524,549
R01 · FY2015 · CA · contact PI
Tumor Cell Biology Training Program$515,160
T32 · FY2015 · CA · contact PI
Chemical Tools for the Study of Dengue Virus Entry$509,576
R01 · FY2015 · AI
Development and Application of Selective Covalent Cdk7 Inhibitors$503,599
R01 · FY2015 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2015 · CA
Chemistry$39,714
P01 · FY2015 · CA · contact PI
Tumor Cell Biology Training Program$37,246
T32 · FY2015 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$684,151
R01 · FY2014 · CA · contact PI
Developing Selective EphA2 Inhibitors for the treatment of Cancer$508,812
R01 · FY2014 · CA · contact PI
Development and Application of Selective Covalent Cdk7 Inhibitors$505,961
R01 · FY2014 · CA · contact PI
Tumor Cell Biology Training Program$497,913
T32 · FY2014 · CA · contact PI
Chemical Tools for the Study of Dengue Virus Entry$421,606
R01 · FY2014 · AI
Targeting ALK and ROS1 in Lung Cancer$320,259
R01 · FY2014 · CA
Chemistry$38,522
P01 · FY2014 · CA · contact PI
Chemical Tools for the Study of Dengue Virus Entry$23,730
R01 · FY2014 · AI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$706,957
R01 · FY2013 · CA · contact PI
Developing Selective EphA2 Inhibitors for the treatment of Cancer$524,549
R01 · FY2013 · CA · contact PI
Targeting ALK and ROS1 in Lung Cancer$330,164
R01 · FY2013 · CA
Host-Targeted, Irreversible Inhibitors of Dengue Virus and Biodefense Viruses$217,345
U54 · FY2013 · AI · contact PI
Chemistry$184,992
P01 · FY2013 · CA · contact PI
Design of inhibitors of drug-resistance protein kinases$416,473
R01 · FY2012 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$332,392
R01 · FY2012 · CA
Host-Targeted, Irreversible Inhibitors of Dengue Virus and Biodefense Viruses$152,986
U54 · FY2012 · AI · contact PI
Covalent Fluorescent Probes for Cancer Cell Detection$135,768
U54 · FY2012 · CA · contact PI
Chemistry$42,819
P01 · FY2012 · CA · contact PI
Design of inhibitors of drug-resistance protein kinases$416,476
R01 · FY2011 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$342,364
R01 · FY2011 · CA
Covalent Fluorescent Probes for Cancer Cell Detection$184,062
U54 · FY2011 · CA · contact PI
Mechanistic Signatures of Drug Responses in Cancer$984,353
RC2 · FY2010 · HG
Design of inhibitors of drug-resistance protein kinases$429,357
R01 · FY2010 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$361,984
R01 · FY2010 · CA
Covalent Fluorescent Probes for Cancer Cell Detection$141,867
U54 · FY2010 · CA · contact PI
Mechanistic Signatures of Drug Responses in Cancer$999,932
RC2 · FY2009 · HG
Design of inhibitors of drug-resistance protein kinases$420,935
R01 · FY2009 · CA · contact PI
EML4-ALK: A Potential Therapeutic Target in Lung Cancer$376,204
R01 · FY2009 · CA
Inhibitors of Kinase Activation$123,747
P41 · FY2009 · GM · contact PI
Design of inhibitors of drug-resistance protein kinases$401,809
R01 · FY2008 · CA · contact PI
Inhibitors of Kinase Activation$367,252
P41 · FY2008 · GM · contact PI
Inhibitors of Kinase Activation$365,090
P41 · FY2007 · GM · contact PI
Inhibitors of Kinase Activation$366,535
P41 · FY2006 · GM · contact PI